- Our vision
- Our pipeline
- Our team
- Contact us
- Language
PB Immune Therapeutics, Inc
contributes to maintaining a healthy life for mankind through the regulation of immune function.
Company vision
The vision of PB Immune Therapeutics is to develop the "Immunomodulatory Therapeutics" capable of controlling immune function (activation, inhibition, and maintenance of homeostasis) and to establish a system that facilitates its safe and accurate clinical application.
Company value
Interest and Passion
Interest and passion are
the matrix of creative thinking
and scientific approach.
Effort and Dedication
From the principles of
basic science, the development
of therapeutic agents is
possible only with diligent efforts
and dedication without
fear of failure.
Sincerity and Fidelity
Only true research results
obtained with sincerity
lead to ultimate success.
Social service
Social service that can return the
benefits received from society to
society is one of the important
values that PB Immune
Therapeutics Co., Ltd. pursues.
Company profile
Company name
PB Immune Therapeutics Inc.
CEO
Chung-Gyu Park
Establishment date
2020.12.18.
Specialized Business Field
Drug Discovery & Development, Precision Immunoassay Service
Main Products
Biologic medical product
Location
71, Ihwajang-gil, Jongno-gu, Seoul, Republic of Korea
Number of Employees
17 (as of 2023. 01.)
Website Address
http://www.pbimmunetherapeutics.com/
Company history
2025
06.17
CSL Research Acceleration Initiative 2025 Finalist
03.19
Selected to Present at KoreaBIO's Early-Stage Investment Program
2024
12.01
Launch of 「Immunedict」 Precision Immunology Analysis Service
11.20
Inaugural Winner of the 2024 Golden Ticket Program (KHIDI & Amgen)
11.03
Renewed Venture Business Certification (Korea)
01.09
Selected as a Pitching Company for Global IR @ JPM 2024
2022
08.01
Selected for a KDDF-Funded New Drug Development Project for Pemphigus Vulgaris
05.01
Selected for a KISED-Funded Start-up Leap-up Package Program
2021
11.03
Venture Business Certification (Korea)
10.01
Selected for a KDDF-Funded New Drug Development Project for Multiple Sclerosis
09.10
Attracted Pre-A Series investment (Atinum)
05.20
Establishment and accreditation of the company-affiliated 「Immunomodulation Research Institute」
05.01
Received an Initial Start-up Package Grant from Korea Institute of Startup & Entrepreneurship Development (KISED)
02.16
Awarded in the ‘National Investor Contest’, a startup festival hosted by the Ministry of Science and Technology
01.04
Business registration
2020
12.18
Established a corporation (PB Immune Therapeutics)
08.01
Received a SNU Startup Project Grant (Task name: Lab-Specialized Startup Leading University)
Platform-to-Bedside,
Pathfinder of the Best therapeutics
PB Immune Therapeutics contributes to the maintenance of human health through immunomodulatory therapeutics.
Collaborative researchers from all over the world
Global-scale collaborative research network
